Check Cap (CHEK) and Hologic (HOLX) Financial Analysis

Check Cap (NASDAQ: CHEK) and Hologic (NASDAQ:HOLX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

22.2% of Check Cap shares are held by institutional investors. Comparatively, 97.6% of Hologic shares are held by institutional investors. 0.8% of Hologic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Check Cap and Hologic’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Check Cap N/A N/A -$8.82 million ($6.42) -0.56
Hologic $3.06 billion 3.29 $755.50 million $2.03 17.95

Hologic has higher revenue and earnings than Check Cap. Check Cap is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Check Cap has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Hologic has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Check Cap and Hologic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Check Cap N/A -129.20% -100.81%
Hologic 34.53% 20.07% 7.11%

Analyst Ratings

This is a summary of current ratings and price targets for Check Cap and Hologic, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check Cap 0 0 2 0 3.00
Hologic 0 4 9 0 2.69

Check Cap currently has a consensus target price of $5.50, suggesting a potential upside of 53.20%. Hologic has a consensus target price of $47.54, suggesting a potential upside of 30.49%. Given Check Cap’s stronger consensus rating and higher possible upside, equities analysts plainly believe Check Cap is more favorable than Hologic.

Summary

Hologic beats Check Cap on 10 of the 12 factors compared between the two stocks.

About Check Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.

About Hologic

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply